AAD 2026Abstract 73841
Efficacy and Safety of Lebrikizumab is Maintained up to 4 Years in Patients With Moderate-to-Severe Atopic Dermatitis
first year of ADlong Long-Term Extension Trial
Weidinger S, Irvine A, Thaçi D, Szepietowski JC, Biedermann T, Agell H, Mihaylov Y, Kostov B, Coll R, Romero W, Reich K
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: Atopic dermatitis & eczema
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.744 · Not in PubMed: details from Crossref